ArticleACS omega2026
Split G‑Quadruplex-Programmed Fluorescent Platform for Low Background Signal and Sensitive Nonsmall Cell Lung Cancer-Related MicroRNA Analysis.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains a leading cause of cancer-related mortality worldwide, with nonsmall cell lung cancer (NSCLC) accounting for approximately 85% of cases. Herein, we develop a split G-quadruplex-programmed fluorescent platform integrating exonuclease III (Exo-III)-assisted dual signal amplification for ultrasensitive detection of the NSCLC-related miRNA let-7a. This platform incorporates two synergistic background-suppression strategies: immobilization of sensing components on a microplate to remove interfering substances and enzymatic cleavage byproducts, and the employment of malachite green as an aggregation-induced emission fluorophore that activates only upon specific G-quadruplex binding. The Exo-III-mediated dual recycling mechanism substantially enhances detection sensitivity. Under optimized conditions, the platform achieves an exceptionally low detection limit of 0.76 fM with a wide linear range from 1 fM to 50 nM. The method exhibits excellent specificity for discriminating let-7a from homologous miRNAs, high recovery rates (97.6-104.3%) in serum samples, and strong correlation with qRT-PCR. This simple, robust platform holds great promise for early NSCLC diagnosis and clinical monitoring.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.